NCT04680767View on ClinicalTrials.gov

A Study of LY3502970 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

July 3, 2021

Study Completion Date

July 3, 2021

Conditions
Healthy
Interventions
DRUG

LY3502970

Administered orally.

DRUG

[¹⁴C]-LY3502970

Administered orally.

Trial Locations (1)

LS2 9LH

Covance Clinical Research, Leeds

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04680767 - A Study of LY3502970 in Healthy Male Participants | Biotech Hunter | Biotech Hunter